Valneva (NASDAQ:VALN) Stock Price Up 2.3% – Should You Buy?

Posted by Amy Steele on Mar 21st, 2025

Valneva SE (NASDAQ:VALN – Get Free Report)’s stock price rose 2.3% on Friday . The company traded as high as $7.45 and last traded at $7.42. Approximately 6,542 shares were traded during trading, a decline of 75% from the average daily volume of 25,882 shares. The stock had previously closed at $7.25.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Valneva in a research report on Friday.

Check Out Our Latest Research Report on VALN

Valneva Trading Down 0.1 %

The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock’s 50-day moving average is $6.29 and its two-hundred day moving average is $5.61. The stock has a market cap of $588.74 million, a P/E ratio of -55.74 and a beta of 1.93.

Valneva (NASDAQ:VALN – Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Equities research analysts anticipate that Valneva SE will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in shares of Valneva SE (NASDAQ:VALN – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.